ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Can String Of Deals Last?
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
